Your browser doesn't support javascript.
loading
Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.
Manolio, Teri A; Hutter, Carolyn M; Avigan, Mark; Cibotti, Ricardo; Davis, Robert L; Denny, Joshua C; Grenade, Lois La; Wheatley, Lisa M; Carrington, Mary N; Chantratita, Wasun; Chung, Wen-Hung; Dalton, Andrea D; Hung, Shuen-Iu; Lee, Ming Ta Michael; Leeder, J Steven; Lertora, Juan J L; Mahasirimongkol, Surakameth; McLeod, Howard L; Mockenhaupt, Maja; Pacanowski, Michael; Phillips, Elizabeth J; Pinheiro, Simone; Pirmohamed, Munir; Sung, Cynthia; Suwankesawong, Wimon; Trepanier, Lauren; Tumminia, Santa J; Veenstra, David; Yuliwulandari, Rika; Shear, Neil H.
Afiliação
  • Manolio TA; Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, Maryland, USA.
  • Hutter CM; Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, Maryland, USA.
  • Avigan M; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Cibotti R; Division of Skin and Rheumatic Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
  • Davis RL; Center for Biomedical Informatics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Denny JC; Departments of Biomedical Informatics and Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Grenade L; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Wheatley LM; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
  • Carrington MN; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA and Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Chantratita W; Medical Genomic Center, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Chung WH; Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Taipei, Linkou, and Keelung, and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Dalton AD; Stevens-Johnson Syndrome Foundation, Westminster, Colorado, USA.
  • Hung SI; Institute and Department of Pharmacology, National Yang-Ming University, Taipei, Taiwan.
  • Lee MTM; Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
  • Leeder JS; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, Missouri, USA.
  • Lertora JJL; Clinical Pharmacology Program, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
  • Mahasirimongkol S; Medical Genetics Center, Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
  • McLeod HL; DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
  • Mockenhaupt M; Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty - University of Freiburg, Freiburg, Germany.
  • Pacanowski M; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Phillips EJ; Department of Medicine, Pharmacology, Oates Institute for Experimental Therapeutics, Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, USA.
  • Pinheiro S; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
  • Pirmohamed M; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Sung C; Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Suwankesawong W; Duke-National University of Singapore Medical School, Singapore.
  • Trepanier L; Health Product Vigilance Center, Thai Food and Drug Administration, Nonthaburi, Thailand.
  • Tumminia SJ; School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin, USA.
  • Veenstra D; Office of the Director, National Eye Institute, Bethesda, Maryland, USA.
  • Yuliwulandari R; Department of Pharmacy, University of Washington, Seattle, Washington, USA.
  • Shear NH; YARSI Research Institute, YARSI University, Jakarta, Indonesia.
Clin Pharmacol Ther ; 103(3): 390-394, 2018 03.
Article em En | MEDLINE | ID: mdl-29105735
ABSTRACT
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is one of the most devastating of adverse drug reactions (ADRs) and was, until recently, essentially unpredictable. With the discovery of several risk alleles for drug-induced SJS/TEN and the demonstration of effectiveness of screening in reducing incidence, the stage is set for implementation of preventive strategies in populations at risk. Yet much remains to be learned about this potentially fatal complication of commonly used drugs.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testes Genéticos / Síndrome de Stevens-Johnson / Predisposição Genética para Doença Tipo de estudo: Incidence_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testes Genéticos / Síndrome de Stevens-Johnson / Predisposição Genética para Doença Tipo de estudo: Incidence_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2018 Tipo de documento: Article